KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease.

Anita Moein, Jakob Ribbing, Moustafa M A Ibrahim, Wenhui Zhang, Nastya Kassir

J Clin Pharmacol 65(10) 1208-1219

PMID40401357
PMCIDPMC12484422
DOI10.1002/jcph.70043
发表日期2025-05-22
入排依据:The study is a Phase III randomized controlled trial of a drug (etrolizumab) but is for Crohn's disease, a non-oncology condition. The primary endpoints are categorical (remission, improvement) analyzed via logistic regression, not time-to-event endpoints like OS/PFS/DFS with Kaplan-Meier or HR.
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。
摘要

摘要

This study aimed to characterize the pharmacokinetics (PK) of etrolizumab, an IgG1-humanized monoclonal anti-β7 integrin antibody, and assess its exposure-response (ER) relationship for key clinical outcomes in patients with moderately-to-severely active Crohn's disease. ER analyses were based on data from Phase 3 BERGAMOT trial, which evaluated etrolizumab at 105 or 210 mg during induction phase and 105 mg during maintenance phase. Population pharmacokinetic analysis was performed to characterize etrolizumab PK and identify influential covariates. ER analyses were conducted at end of induction and maintenance for clinical remission, endoscopic improvement, and endoscopic remission. ER modeling was performed using logistic regression, and full covariate model was used to examine the impact of baseline covariates on clinical outcomes. Pharmacokinetics of etrolizumab was best characterized using a two-compartment model with first-order absorption, demonstrating a time-dependent decrease in clearance. Typical maximum reduction of clearance was 22.0% (95% CI: 20.5%-23.5%) with onset half-life of 3.45 (95% CI: 2.84-4.04) weeks. Baseline body weight, albumin, and C-reactive protein were the most impactful covariates for etrolizumab exposure. Based on population PK results, trough concentration at Week 4 of induction was selected as exposure metric. Etrolizumab exposure-response slope was significant (P < .05) for clinical remission, endoscopic improvement, and endoscopic remission final models in maintenance phase, but none of final ER models of induction phase. For all induction ER endpoints, tumor necrosis factor (TNF)-naive patients had significantly higher probability of a favorable outcome at end of induction compared to TNF-experienced patients. In summary, exposure-response was more evident at end of maintenance than at end of induction.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Forest plot showing the final etrolizumab pharmacokinetic model estimates of covariates effects on the Week‐4 trough concentration. Forest plot showing the final etrolizumab PK model estimates of covariate effects on the Week‐4 trough concentration. The closed symbols represent the point estimates and the whiskers represent the 95% CI, based on the NONMEM covariance matrix. The vertical, dashed line is marking no change (a ratio of one), compared to the reference patient. The x‐axis is on log scale, since ratios 2/3 and 1.5 are of corresponding impact, just as ratios 0.8 and 1.25 are. For continuous covariates, the impact has been shown for the 2.5th and 97.5th percentile of the covariate (across the subjects in the PK analysis data set). For SES‐CD, since values were only available in CD patients, the percentiles were based on CD patients only. In particular for ADA titer, the 2.5th and median values were both zero titer (i.e., the reference) and therefore only positive titer was illustrated. The positive titer here represents the 97.5th percentile across subject's highest titer value during the first 40 days. The numbers on the right hand of the plot represent point estimates (95% CIs) of the ratio to the reference patient (with baseline values: 72 kg body weight, 41 g/L albumin, 5.48 mg/L CRP, SESCD = 12 and 94.9 mL/min/1.73 m 2 GFR, being a patient with UC without prior anti‐TNF, with left‐sided colitis, who was ADA negative (at least) until Week 4). ADA, anti‐drug antibody; ALB, albumin; CD, Crohn's disease; CI, confidence interval; CRP, C‐reactive protein; GFR, estimated glomerular filtration rate; SES‐CD, simplified endoscopic score for Crohn's disease; TNF, tumor necrosis factor; UC, ulcerative colitis; WT, body weight.
非 KM Figure
Figure 2Figure 2 Prediction‐corrected visual predictive check of etrolizumab concentrations versus time since first dose, for the final population pharmacokinetic model, stratified by study. Etrolizumab concentrations are displayed versus time since first dose. The solid and dashed red lines represent the median, 10th, and 90th percentiles of the observations; the shaded red and blue areas represent the 95% confidence interval of the median, 10th, and 90th percentiles predicted by the model. The observed data are indicated by open circles, but since the y‐scale has been cut at 70 µg/mL, eight observations with higher prediction‐corrected values are not visible in the upper panels.
非 KM Figure
Figure 3Figure 3 Percentage of subjects achieving a positive outcome per etrolizumab exposure tertiles based on predicted etrolizumab C trough,W4,adjusted , stratified by phase and type of outcome for the analysis data set. Percentage numbers and bars represent the percentage achieving the outcome with bars colored by the treatment (active vs placebo). Error bars represent the 95% confidence intervals. The text displayed inside the bars represent the number of subjects 1 with the positive outcome over the total number of patients. 1 Only patients who achieved a CDAI‐70 response were eligible to continue into the maintenance phase of the trial.
非 KM Figure
Figure 4Figure 4 Significant covariates at maintenance. (a) Predicted proportion achieving clinical remission at maintenance versus etrolizumab C trough,W4 , adjusted , stratified by percentiles of albumin at baseline. (b) Predicted proportion achieving clinical remission at maintenance versus etrolizumab C trough,W4 , adjusted , stratified by percentiles of CDAI scores at baseline. (c) Predicted proportion achieving endoscopic remission at maintenance versus etrolizumab C trough,W4 , adjusted , stratified by percentiles of SES‐CD at baseline. (d) Predicted proportion achieving clinical remission at maintenance versus etrolizumab C trough,W4 , adjusted , stratified by sex. (e) Predicted proportion achieving clinical remission at maintenance versus etrolizumab C trough,W4 , adjusted , stratified by prior TNF. (f) Predicted proportion achieving endoscopic improvement at maintenance versus etrolizumab C trough,W4 , adjusted , at Week 4 of induction, stratified by smoking status. (g) Predicted proportion achieving endoscopic improvement at maintenance versus etrolizumab C trough,W4 , adjusted , stratified by disease location. Colon only was not significantly different from ileum and colon, and therefore the two are predicted to be identical, based on the final model. Colon only is not visible in the graph, as overlaid by the group with ileum and colon disease location. (h) Predicted proportion achieving endoscopic remission at maintenance versus etrolizumab C trough,W4 , adjusted , stratified by disease location. Ileum only was not significantly different from ileum and colon, and therefore the two are predicted to be identical, based on the final model. Ileum and colon is not visible in the graph, as overlaid by the group with ileum only disease location.
非 KM Figure